In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) “spike” that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?
Barton F. Haynes et al.
Want To Publish your Group Article?
Click HERE to send us your group Article for publishing on our website.
- alzheimer Alzheimers Disease animal model antibiotic resistance antibiotics Bacteria Brain breast cancer cancer cell-signaling clinical trials CRISPR diabetes disease/medicine DNA drug drug research Gene Expression general health Gene therapy Genetics genetics & genomics Genomics HIV immunology immunotherapy infectious disease Malaria microbiology microbiome mutation neuroscience new therapy obesity Parkinson's disease stem cells T cells techniques therapy treatment tumor vaccine virology virus Zika virus